We further found that for predicting 6-month OS, KRAS and TP53 mutations in ctDNA had higher AUCs than the other clinicopathologic characteristics, and previous studies [56, 62] also showed that ctDNA was more accurate for monitoring chemotherapy efficacy than CA19-9, the major prognostic circulating tumor marker for PDAC. Here, KRAS is linked to neoplasm.